AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25166221
Drug: BF Spiromax
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BF Spiromax 160+9 μg b.i.d.
Trial: 25166221
Drug: Symbicort Turbohaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Turbohaler 200+12 μg b.i.d.
Trial: 10916717
Drug: 3-day family
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day family medicine preceptorship
Trial: 31412770
Drug: QLB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLB group (0.4 cc/kg of 0.3% ropivacaine)
Trial: 31412770
Drug: C group
RxNorm normalized name: chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C group (0.4 cc/kg of 0.9% saline)
Trial: 29943093
Drug: Levodopa/carbidopa (100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa (100/25 mg)
Trial: 27765726
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride (30 mg/250 ml) gastric infusion for 6 hours
Trial: 27765726
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride (30 mg) immediate-release tablets
Trial: 27765726
Drug: Gastric infusion
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric infusion of trospium chloride
Trial: 21987386
Drug: Upfront zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Upfront zoledronic acid (4 mg intravenously every 6 months for 5 years)
Trial: 21987386
Drug: Delayed-start zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delayed-start zoledronic acid (4 mg intravenously every 6 months for 5 years)
Trial: 15907848
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg/day) and Vitamin E (400 IU/day)
Trial: 8320005
Drug: Soft laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft laser treatment (As-Ga and He-Ne)
Trial: 3529799
Drug: Oral physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physostigmine (10 mg/day for 3 days)
Trial: 3529799
Drug: Oral neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neostigmine (45 mg/day for 3 days)
Trial: 3529799
Drug: Intravenous physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous physostigmine (1 mg)
Trial: 3529799
Drug: Intravenous neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous neostigmine (1.5 mg)
Trial: 31265100
Drug: Tanezumab 2.5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 2.5/5 mg
Trial: 22566747
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly (ExQW)
Trial: 26214887
Drug: Gukang Capsules
RxNorm normalized name: Guang Guo Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gukang Capsules plus Calcium Carbonate Tablets
Trial: 26214887
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate Tablets
Trial: 23953056
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg/d continuously
Trial: 23953056
Drug: Lapatinib 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1250 mg/d continuously plus capecitabine 2000 mg/m2 per day on days 1-14 of each 21-d cycle
Trial: 21148503
Drug: Chloroquine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (50 mg/kg, 6 divided doses over 3 days)
Trial: 18324564
Drug: Pharmacotherapy-aided quit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy-aided quit attempt
Trial: 8922792
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg daily (with some patients receiving 800 mg for part of treatment)
Trial: 8922792
Drug: Fluconazole 800
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 800 mg daily
Trial: 28167470
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with Shexiang baoxin pills therapy
Trial: 28167470
Drug: Clopidogrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel therapy (Control)
Trial: 26319228
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) infusion set (microneedle design B)
Trial: 26319228
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) infusion set (Rapid-D)
Trial: 26319228
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) infusion set
Trial: 26319228
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) devices (MiniMed and Animas pumps)
Trial: 26319228
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) and Subcutaneous (SC) infusion sets
Trial: 19090877
Drug: Trandolapril/verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/verapamil SR (T/V) fixed-dose combination (FDC)
Trial: 19090877
Drug: Benazepril/amlodipine (B/A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril/amlodipine (B/A) fixed-dose combination (FDC)
Trial: 16868321
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1 mL of 2% prilocaine using the peppering technique
Trial: 16868321
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 2% prilocaine combined with 2 mL of autologous blood
Trial: 16868321
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 2% prilocaine mixed with 40 mg of methylprednisolone acetate
Trial: 12956200
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nail lacquer with oral antifungal agent
Trial: 12956200
Drug: Other topical
RxNorm normalized name: Other topical products for joint and muscular pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other topical agents
Trial: 6142748
Drug: Oral pirbuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pirbuterol 15 mg
Trial: 6142748
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (500 microgram and 5 mg)
Trial: 28986072
Drug: Medication abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication abortion
Trial: 25456022
Drug: Cumin powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumin powder (3 g/d with yogurt for 3 months)
Trial: 14741074
Drug: Sympathyl (study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sympathyl (study drug)
Trial: 27460262
Drug: Pectin-coated fortified
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin-coated fortified rice with 400 μg 13C5-PteGlu
Trial: 27460262
Drug: Uncoated fortified
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uncoated fortified rice with 400 μg 13C5-PteGlu
Trial: 27460262
Drug: Aqueous 400
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous 400 μg 13C5-PteGlu
Trial: 26047890
Drug: Esmirtazapine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmirtazapine 1.5 mg
Trial: 26047892
Drug: Esmirtazapine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmirtazapine 4.5 mg
Trial: 16317969
Drug: Custom trays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom trays with 10% carbamide peroxide gel worn overnight for 2 weeks
Trial: 16317969
Drug: 10% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydrogen peroxide polyethylene strips worn for 30 minutes twice a day for 2 weeks
Trial: 9596324
Drug: Atropine premedication
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine premedication (0.6 mg)
Trial: 9596324
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (1 mL)
Trial: 7674696
Drug: Current therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapies for acute ischemic syndromes
Trial: 1982831
Drug: EPO subcutaneous
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO subcutaneous route (s.c) at doses of 20 u/kg daily
Trial: 1982831
Drug: EPO subcutaneous
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO subcutaneous route (s.c) at doses of 2000 units twice a week
Trial: 1982831
Drug: EPO intraperitoneal
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO intraperitoneal route (i.p) at doses of 4000 u/day, three days a week
Trial: 1982831
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of EPO doses and outcomes between groups
Trial: 369361
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg atropine sulfate
Trial: 26111923
Drug: Tailored post-session
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored post-session D-cycloserine (DCS) administration
Trial: 15230794
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg intramuscular)
Trial: 15230794
Drug: Hyoscine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine (20 mg intramuscular)
Trial: 11878523
Drug: Epidural 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 0.2% bupivacaine 8 ml h(‐1) (bupi group)
Trial: 11878523
Drug: Epidural 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 0.2% bupivacaine/morphine 50 microg at 4 ml h(‐1) (bupi/morph group)
Trial: 8169617
Drug: Nimodipine administration
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine administration
Trial: 31233255
Drug: Intrathecal ziconotide
RxNorm normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal ziconotide (average dose of 7.2µg per day)
Trial: 27914822
Drug: Sodium thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium thiosulfate 16 g/m2 intravenously 6 hours after each cisplatin dose
Trial: 20032496
Drug: (SC)GOS/(LC)FOS/AOS (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (SC)GOS/(LC)FOS/AOS (1.5 g . kg(‐1) . d(‐1))
Trial: 15819987
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IVC + and IVR < 1
Trial: 11835452
Drug: Nabilone (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (synthetic cannabinoid receptor agonist)
Trial: 2301717
Drug: Combined systemic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined systemic clindamycin and topical ampicillin
Trial: 7470203
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of cholestyramine twice daily
Trial: 7470203
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g of cholestyramine twice daily
Trial: 7470203
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g of cholestyramine daily
Trial: 7470203
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g of cholestyramine daily
Trial: 28426903
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (Btx‐A) - 50 units in 2.5 ml sterile saline
Trial: 28426903
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline (placebo) - 2.5 ml
Trial: 25616206
Drug: Intravenous Mg
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Mg sulphate 40 mg kg(‐1) followed by an infusion of 10 mg kg(‐1) h(‐1)
Trial: 23348071
Drug: First quartile
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First quartile of fruit intake (23 g/day)
Trial: 17530683
Drug: Operant-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operant-behavioral therapy (OBT)
Trial: 16490090
Drug: Both propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both propofol formulations (LCT and MCT/LCT)
Trial: 14658184
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding 48 to 72 hours after total laryngectomy
Trial: 14658184
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding 10 to 12 days after total laryngectomy
Trial: 6410450
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (up to 600 mg)
Trial: 28850681
Drug: 8-mg dexamethasone
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg dexamethasone every 8 hours for up to 4 days after surgery
Trial: 23871259
Drug: Oral pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pressure therapy (OPT)
Trial: 16940094
Drug: Amoxicillin (AMX)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMX) 2 g
Trial: 16940094
Drug: Clindamycin (CLI)
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin (CLI) 600 mg
Trial: 16940094
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (MXF) 400 mg
Trial: 15302567
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg per day (40 mg twice daily)
Trial: 11753267
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's Wort (300 mg, three times a day for 14 days)
Trial: 9266538
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 supplementation (90 mg/day)
Trial: 8440431
Drug: Zaldaride maleate
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaldaride maleate 20 mg
Trial: 3758151
Drug: Topical beclomethasone
RxNorm normalized name: beclomethasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beclomethasone dipropionate suspension
Trial: 31473111
Drug: Cefepime 1
RxNorm normalized name: cefepime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 1 g administered intravenously every 8 h for an average of 10.5 days
Trial: 31473111
Drug: Meropenem 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 0.5 g administered intravenously every 8 h for an average of 10.5 days
Trial: 23098170
Drug: Ingesting the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingesting the entire daily dose of ≥1 hypertension medication at bedtime
Trial: 14532316
Drug: Methotrexate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (15 to 20 mg/wk)
Trial: 10506633
Drug: Dexamethasone 0.75
RxNorm normalized name: dexamethasone 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.75 mg qid
Trial: 10506633
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 800 mg orally every day
Trial: 10506633
Drug: Fluoxymesterone 10
RxNorm normalized name: fluoxymesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxymesterone 10 mg orally bid
Trial: 26509382
Drug: Low-dose CO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CO inhalation (1.2 mL·kg(‐1) body mass)
Trial: 26509382
Drug: Low-dose CO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CO inhalation
Trial: 22731245
Drug: Forskolin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forskolin and rutin (2 tablets per day)
Trial: 22731245
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal topical therapy only)
Trial: 20668826
Drug: Hyperbaric levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric levobupivacaine 1.5 mg (perianal)
Trial: 20668826
Drug: Hyperbaric levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric levobupivacaine 6 mg (saddle)
Trial: 11878059
Drug: Xenical (orlistat)
RxNorm normalized name: orlistat Oral Capsule [Xenical]
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xenical (orlistat) 360 mg/day with diet
Trial: 9536565
Drug: Sumatriptan 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 12.5 mg
Trial: 23325368
Drug: Sumatriptan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (both doses)
Trial: 7633301
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of apomorphine (0.005 mg/kg) in heroin addicts
Trial: 7633301
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of apomorphine (0.005 mg/kg) in healthy volunteers
Trial: 2673693
Drug: Miglitol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (300 mg/day)
Trial: 363236
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (20 g)
Trial: 363236
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid (in capsules)
Trial: 12947434
Drug: Glycaemic glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycaemic glucose equivalent (GGE) doses of 10 and 20 GGE for yams, biscuits, white rice, and porridge; 24 and 48 GGE for 2-minute noodles
Trial: 9225069
Drug: Granulocyte colony‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) and erythropoietin (EPO)
Trial: 1546144
Drug: Moclobemide 200
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 200 mg b.i.d.
Trial: 7954488
Drug: Brofaromine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine 75 mg b.i.d.
Trial: 7954488
Drug: Mianserin 10
RxNorm normalized name: mianserin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 10 mg t.i.d.
Trial: 7954488
Drug: Doxepin 25
RxNorm normalized name: doxepin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 25 mg t.i.d.
Trial: 7954488
Drug: Brofaromine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (both doses)
Trial: 7954488
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Moclobemide and Brofaromine)
Trial: 2359974
Drug: Viscous bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscous bolus (syrup; viscosity, 102 centipoise) at varying volumes (5, 10, 15, 20 ml)
Trial: 2359974
Drug: Non-viscous bolus
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-viscous bolus (water; viscosity, 0.89 centipoise) at varying volumes (5, 10, 15, 20 ml)
Trial: 12556685
Drug: 2% PRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% PRO 2000 Gel, once or twice daily for 14 days
Trial: 12556685
Drug: 4% PRO
RxNorm normalized name: Stanimax 2.84% Pro Perio Mouthwash Dental Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% PRO 2000 Gel, twice daily for 14 days
Trial: 8546555
Drug: Influenza and
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza and pneumococcal vaccines